Randomized, Double-blind, Placebo Controlled, Parallel-group, Prospective Clinical Study to Analyse the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure
Phase of Trial: Phase II
Latest Information Update: 24 Jun 2019
Price : $35 *
At a glance
- Drugs Empagliflozin (Primary)
- Indications Chronic heart failure
- Focus Therapeutic Use
- Acronyms ELSI
- 24 Jun 2019 Results assessing vascular remodeling of retinal vessels presented at the 29th European Meeting on Hypertension and Cardiovascular Protection.
- 31 Aug 2018 Biomarkers information updated
- 11 Oct 2017 Status changed from not yet recruiting to recruiting.